Crystalys Therapeutics Raises $205M in Series A
Crystalys Therapeutics has successfully raised $205M in a Series A led by Novo Holdings, SR One, Catalys Pacific.
Company Overview
Crystalys Therapeutics is a HealthTech company headquartered in San Diego, CA, founded in 2024 with 40+ employees.
Biopharma company developing novel treatments for gout and related inflammatory diseases
Fundraising Details
- Amount Raised: $205M
- Round Type: Series A
- Date: 2025-10-01
- Investors: Novo Holdings, SR One, Catalys Pacific
About Crystalys Therapeutics
Biopharma company developing novel treatments for gout and related inflammatory diseases The company is positioned in the HealthTech sector, serving a growing market with innovative solutions.
Key Information
- Headquarters: San Diego, CA
- Founded: 2024
- Team Size: 40+
- Industry: HealthTech
What This Means
This funding round demonstrates strong investor confidence in Crystalys Therapeutics's vision and execution. The capital will likely be used to:
- Scale Operations: Expand the team and operational capacity
- Product Development: Enhance existing products and develop new features
- Market Expansion: Enter new markets and strengthen presence in existing ones
- Technology Investment: Invest in infrastructure and technology capabilities
Industry Context
The HealthTech sector continues to attract significant investment as companies innovate to meet evolving market demands. Crystalys Therapeutics's successful fundraising reflects the strong fundamentals and growth potential in this space.
Looking Ahead
With this new capital, Crystalys Therapeutics is well-positioned to execute on its growth strategy and continue building innovative solutions in the HealthTech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.
---
This fundraising news was reported on 2025-10-01. For more information about Crystalys Therapeutics, visit their headquarters at San Diego, CA.
